チロキサポール
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/06 22:02:36」(JST)
[Wiki en表示]
Tyloxapol
|
| Systematic (IUPAC) name |
|
formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Identifiers |
| CAS Registry Number |
25301-02-4 Y |
| ATC code |
R05CA01 |
| PubChem |
CID: 71388 |
| DrugBank |
DB06439 N |
| ChemSpider |
11052515 N |
| UNII |
Y27PUL9H56 N |
| KEGG |
D03261 N |
| ChEMBL |
CHEMBL1201548 N |
| Chemical data |
| Formula |
(C15H21O(C2H4O)m)n |
| Molecular mass |
variable |
| N (what is this?) (verify) |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an Expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire
References
- ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association 86 (1): 46–52. PMC 2607653. PMID 8151722.
- ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ^ Drugs.com: Tyloxapol definition
- ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.
|
Cough and cold preparations (R05)
|
|
| Expectorants |
- Althea root
- Antimony pentasulfide
- Creosote
- Guaiacolsulfonate
- Guaifenesin
- Ipecacuanha (Syrup of ipecac)
- Levoverbenone
- Potassium iodide
- Senega
- Tyloxapol
- Ammonium Chloride
|
|
| Mucolytics |
- Acetylcysteine
- Ambroxol
- Bromhexine
- Carbocisteine
- Domiodol
- Dornase alfa
- Eprazinone
- Erdosteine
- Letosteine
- Mannitol
- Mesna
- Neltenexine
- Sobrerol
- Stepronin
- Tiopronin
|
|
| Cough suppressants |
Opium alkaloids,
opioids,
and derivatives |
- Acetyldihydrocodeine
- Benzylmorphine
- Butorphanol
- Codeine
- Dextromethorphan
- Dihydrocodeine
- Dimemorfan
- Droxypropine
- Ethylmorphine
- Heroin
- Hydrocodone
- Hydromorphone
- Isoaminile
- Laudanum
- Levomethadone
- Levopropoxyphene
- Methadone
- Nicocodeine
- Nicodicodeine
- Normethadone
- Noscapine
- Pholcodine
- Thebacon
- Tipepidine
|
|
| Other |
- Benzonatate
- Benproperine
- Bibenzonium bromide
- Butamirate
- Clobutinol
- Clofedanol
- Cloperastine
- Diphenhydramine
- Dibunate
- Dimethoxanate
- Dropropizine
- Fedrilate
- Glaucine
- Levodropropizine
- Meprotixol
- Morclofone
- Nepinalone
- Oxolamine
- Oxeladin
- Pentoxyverine
- Pipazetate
- Prenoxdiazine
- Piperidione
- Zipeprol
|
|
|
|
Index of the respiratory system
|
|
| Description |
- Anatomy
- Physiology
- Development
|
|
| Disease |
- Congenital
- Neoplasms and cancer
- Chest trauma
- Infection
- common cold
- pneumonia
- tuberculosis
- Other
- Symptoms and signs
|
|
| Treatment |
- Procedures
- Drugs
- nasal
- throat
- obstructive airway diseases
- cough and cold
- histaminergics
- pulmonary arterial hypertension
- other
- Surgery
|
|
|
English Journal
- Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.
- Mehta SK, Jindal N.SourceDepartment of Chemistry and Center of Advanced Studies in Chemistry, Panjab University, Chandigarh 160 014, India.
- Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2012 Jul 17;101C:434-441. [Epub ahead of print]
- The present study delineates the formulation of niosomes from biocompatible surfactant Tyloxapol and their potential as drug delivery system for anti-tuberculosis drugs. Drug loaded niosomes have a size of 150nm with a loading efficiency of 97.95±0.2, 98.89±0.2 and 99.50±0.2% for rifampicin (RIF)
- PMID 23010052
- The transcription factor HNF-4α: a key factor of the intestinal uptake of fatty acids in mouse.
- Frochot V, Alqub M, Cattin AL, Carrière V, Houllier A, Baraille F, Barbot L, Saint-Just S, Ribeiro A, Lacasa M, Cardot P, Chambaz J, Rousset M, Lacorte JM.SourceCentre de Recherche des Cordeliers, Université Pierre et Marie Curie, UMRS, Paris, France.
- American journal of physiology. Gastrointestinal and liver physiology.Am J Physiol Gastrointest Liver Physiol.2012 Jun 1;302(11):G1253-63. Epub 2012 Mar 29.
- With an excessive postprandial accumulation of intestine-derived, triglyceride-rich lipoproteins being a risk factor of cardiovascular diseases, it is essential to characterize the mechanisms controlling the intestinal absorption of dietary lipids. Our aim was to investigate the role of the transcri
- PMID 22461026
Japanese Journal
- Effect of Pulmonary Surfactant and Phospholipid Hexadecanol Tyloxapol on Recombinant Human-Insulin Absorption from Intratracheally Administered Dry Powders in Diabetic Rats
- Zheng Jianheng,Zhang Ge,Lu Yang [他],Fang Fang,He Jiake,Li Ning,Talbi Amer,Zhang Ying,Tang Yue,Zhu Jiabi,Chen Xijing
- Chemical and Pharmaceutical Bulletin 58(12), 1612-1616, 2010
- … The purpose of the present study was to evaluate the enhancement effect of the natural pulmonary surfactant (PS) or its artificial substitute, phospholipid hexadecanol tyloxapol (PHT) on the bioavailability and hypoglycemic activity of recombinant human insulin (rh-insulin) in a pulmonary delivery system. …
- NAID 130000405689
- 保存剤を含有していない0.125%チロキサポール吸入液における一回量包装の有用性
- 杉山 一覚,高橋 淳一,井手上 寿美佳,金子 幸恵,松本 富夫,建部 守
- 病院薬学 23(3), 225-230, 1997-06-10
- … By comparing the usual method of measuring medication dosage in medical cups in our hospital (A packages) with newly developed one dose packages (B, C packages) the stability of the ingredients, the sterility of the material, and the accuracy of the correctness of the measuring the samples, we assessed the usefulness of one dose packages of preservative-free 0.125%tyloxapol solutions for the administration of oral medications. …
- NAID 110001799656
- ステロイドの気管支鏡下局所投与が有用であった無気肺合併気管支喘息の 1 例
- 石浦 嘉久,藤村 政樹,南 真司,渡辺 和良,安井 正英,新谷 博元,松田 保
- 気管支学 : 日本気管支研究会雑誌 17(2), 186-190, 1995-03-25
- 症例は66歳, 女性。喘鳴と呼吸困難を主訴として入院した。粘稠痰による無気肺を合併し, 気管支喘息発作が遷延したため, 気管支鏡下に吸引・洗浄し, 水溶性プレドニゾロン10mg, ゲンタマイシン10mg, チロキサポール3.75mgを局所投与した。過去に吸引・洗浄のみを施行した場合に比べ, 速やかに発作が消失し, 今後同様の病態に対しステロイド, 抗菌薬と界面活性剤の局所注入療法が有効である可能性 …
- NAID 110002818703
Related Links
- Buy Tyloxapol (CAS 25301-02-4), a nonionic liquid polymer of the alkyl aryl polyether alcohol type, from Santa Cruz. MF: C17H30O4, MW: 298.42(monomer) ... 同義語 Ethoxylated p-tert-octylphenol formaldehyde polymer
- Sigma-Aldrich offers Sigma-T8761, Tyloxapol for your research needs. Find product specific information including CAS, MSDS, protocols and references. ... Application Do you have application information on this product that ...
★リンクテーブル★
[★]
- 英
- tyloxapol
- 商
- アレベール